Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines

Digestive Diseases and Sciences

Volumn 56, Issue 6, 2011, Pages 1876-1883

  Carr, Brian I ^a,b,c   Wang, Ziqiu ^a   Wang, Meifung ^a   Wei, Gang ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

AFP; DCP; HCC; Responses; Vitamin K

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; PHYTOMENADIONE; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE;

ABSENCE OF SIDE EFFECTS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HEPG2; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN CELL; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; NICK END LABELING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH; WESTERN BLOTTING;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; PROTEIN PRECURSORS; PROTHROMBIN; TUMOR MARKERS, BIOLOGICAL; VITAMIN K 1;

EID: 79959737732     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-010-1521-x     Document Type: Article

References (32)

1. El-Serag KR. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225-249.
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
4. Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009;16:2795-2804.
5. Fujiki M, Takada Y, Ogura Y, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant. 2009;9:2362-2371.
6. Baek YH, Lee JH, Jang JS, et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology. 2009;56:763-767.
7. Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110-118.
8. Kitai S, Kudo M, Minami Y, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology. 2008;75:83-90.
9. Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci. 2007;52:776-782.
10. Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561-569. (Pubitemid 32105702)
11. Hasegawa K, Imamura H, Ijichi M, et al. Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection. J Gastrointest Surg. 2008;12:858-866.
12. Li ZQ, He FY, Stehle CJ, Wang Z, Kar S. Finn FM, Carr BI. Vitamin K uptake in hepatocytes and hepatoma cells. Life Sci. 2002;70:2085-2100. (Pubitemid 34219460)
13. Hitomi M, Yokoyama F, Kita Y, et al. Antitumor effects of vitamins K1, K2, and K3 on hepatocellular carcinoma in vitro and in vivo. Int J Oncol. 2005;26:713-720.
14. Hitomi M, Nonomura T, Yokoyama F, et al. In vitro and in vivo antitumor effects of vitamin K5 on hepatocellular carcinoma. Int J Oncol. 2005;26:1337-1344.
15. Kuriyama S, Hitomi M, Yoshiji H, et al. Vitamins K2, K3, and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol. 2005;2:505-511.
16. Matsumoto K, Okano J, Nagahara T, Murawaki Y. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. Int J Oncol. 2006;6:1501-1508.
17. Hotta N, Ayada M, Sato K, et al. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology. 2007;54:2073-2077.
18. Mizuta T, Ozaki I, Eguchi Y, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer. 2006;4:867-872. (Pubitemid 43238454)
19. Bolton-Smith C, McMurdo MET, Paterson CR et al. Two-year randomized controlled trial of vitamin K1 and vitamin D3 plus calcium on the bone health of older women. J Bone and Mineral Res. 2007;22:509-519. (Pubitemid 47457427)
20. Iwamoto J, Takeda T, Sato Y. Role of vitamin K2 in the treatment of postmenopausal osteoporosis. Cann Drug Safety. 2006;1:87-97.
21. Thane CW, Wang LY, Coward WA. Plasma phylloquinone (vitamin K1) concentration and its relationship to intake in British adults aged 19-64 years. Br J Nutr. 2006;96:1116-1124. (Pubitemid 46470175)
22. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
23. Otsuka M, Kato N, Shao RX, et al. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology. 2004;40:243-251. (Pubitemid 38868943)
24. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S. Vitamin K2 induces phosphorylation of protein kinase A and expression of novel target genes in osteoblastic cells. J Mol Endocrinol. 2007;39:239-247. (Pubitemid 350047645)
25. Schramm K, Niehof M, Radziwill G, Rommel C, Moelling K. Phosphorylation of c-Raf-1 by protein kinase A interferes with activation. Biochem Biophys Res Commun. 1994;201:740-747. (Pubitemid 24206934)
26. Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H, Kolch W. Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol. 2002;22:3237-3246. (Pubitemid 34453966)
27. Wei G, Wang M, Hyslop T, Wang Z, Carr BI. Vitamin K enhancement of Sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer. 2010; June 7 Epub.
28. Sakakima Y, Hayakawa A, Nagasaka T, Nakao A. Prevention of hepatocaarcinogenesis with phosphatidylcholine and menaquinone-4: in vitro and in vivo experiments. J Hepatol. 2007;47:83-92. (Pubitemid 46817686)
29. Habu D, Shiomi S, Tamori A, Takeda T, Kubo S, Nishiguchi S. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA. 2004;292:358-361. (Pubitemid 38944260)
30. Li MS, Ma QL, Cheng Q, et al. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J Gastroenterol. 2005;11:2564-2569.
31. Yang X, Zhang Y, Zhang L, Zhang L, Mao J. Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett. 2008;271:281-293.
32. Li M, Li H, Li C, et al. Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells. Int J Cancer. 2009;124:2845-2854.